A copper chelate selectively triggers apoptosis in myeloid-derived suppressor cells in a drug-resistant tumor model and enhances antitumor immune response

Immunopharmacology and Immunotoxicology

Volumn 36, Issue 2, 2014, Pages 165-175

  Chakraborty, Paramita ^a   Das, Satyajit ^a   Banerjee, Kaushik ^a   Sinha, Abhinaba ^a   Roy, Susmita ^b   Chatterjee, Mitali ^b   Choudhuri, Soumitra Kumar ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Drug resistant cancer; Fas mediated apoptosis; Immunomodulation; Schiff base metal chelates; Th1 response

Indexed keywords

COPPER N(2 HYDROXY ACETOPHENONE)GLYCINATE; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; IMMUNOMODULATING AGENT; METAL CHELATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES FLUID; BONE MARROW CELL; CANCER RESISTANCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; SUPPRESSOR CELL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR MODEL;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHELATING AGENTS; COPPER; DOXORUBICIN; LYMPHOCYTE ACTIVATION; MICE; MYELOID CELLS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 84897855568     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2014.897727     Document Type: Article

References (47)

1. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1: 54-67.
2. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011;25: 2559-2572.
3. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5: 263-274.
4. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9: 162-174.
5. Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008;111: 219-228.
6. Sinha P, Clements VK, Bunt SK, et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007;179: 977-983.
7. Hanson EM, Clements VK, Sinha P, et al. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009;183: 937-944.
8. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117: 1155-1166.
9. Kao J, Ko EC, Sikora AT, et al. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011;77: 12-19.
10. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003;63: 4441-4449.
11. Fricke I, Mirza N, Dupont J, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007;13: 4840-4848.
12. Zhenga Y, Xub M, Li X, et al. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol 2013;54: 74-83.
13. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11: 6713-6721.
14. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70: 3052-3061.
15. Terabe M, Matsui S, Park JM, et al. Transforming growth factorbeta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte- mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198: 1741-1752.
16. Talmadge JE, Hood KC, Zobel LC, et al. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol 2007;7: 140-151.
17. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65: 3044-3048.
18. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203: 2691-2702.
19. De Santo C, Serafini P, Marigo I, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 2005; 102: 4185-4190.
20. Yu J, Du W, Yan F, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013;190: 3783-3797.
21. Majumder S, Panda GS, Kumar Choudhuri S. Synthesis, characterization and biological properties of a novel copper complex. Eur J Med Chem 2003;38: 893-898.
22. Mookerjee A, Mookerjee Basu J, Dutta P, et al. Overcoming drugresistant cancer by a newly developed copper chelate through hostprotective cytokine-mediated apoptosis. Clin Cancer Res 2006;12: 4339-4349.
23. Chatterjee S, Mookerjee A, Basu JM, et al. A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells. PLoS One 2009;4:e7048.
24. Chakraborty P, Chatterjee S, Ganguly A, et al. Reprogramming of TAM toward proimmunogenic type through regulation of MAP kinases using a redox-active copper chelate. J Leukoc Biol 2012;91: 609-619.
25. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204: 1463-1474.
26. Bronte V, Wang M, Overwijk WW, et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol 1998;161: 5313-5320.
27. Makarenkova VP, Bansal V, Matta BM, et al. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 2006;176: 2085-2094.
28. Zhu B, Bando Y, Xiao S, et al. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007;179: 5228-5237.
29. Friche E, Danks MK, Beck WT. Characterization of tumor cell resistance to 40-deoxy-40-iododoxorubicin developed in Ehrlich ascites cells in vivo. Cancer Res 1992;52: 5701-5706.
30. Choudhuri SK, Chatterjee A. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(Nphenyl) hydroxamic acid in vitro. Anticancer Drugs 1998;9: 825-832.
31. Majumder S, Dutta P, Mookerjee A, Choudhuri SK. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Chem Biol Interact 2006; 159: 90-103.
32. Chatterjee S, Das S, Chakraborty P, et al. Myeloid derived suppressor cells (MDSCs) can induce the generation of Th17 response from naive CD4+ T cells. Immunobiology 2013;218: 718-724.
33. Ganguly A, Basu S, Banerjee K, et al. Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis. Mol Biosyst 2011;7: 1701-1712.
34. Sinha P, Chornoguz O, Clements VK, et al. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 2011;117: 5381-5390.
35. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407: 770-776.
36. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1: 469-474.
37. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2: 48-58.
38. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7: 513-520.
39. Ugel S, Delpozzo F, Desantis G, et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009;9: 470-481.
40. Liu Q, Zhang M, Jiang X, et al. miR-223 suppresses differentiation of tumor-induced CD11b(+) Gr1(+) myeloid-derived suppressor cells from bone marrow cells. Int J Cancer 2011;129: 2662-2673.
41. Lu B. The molecular mechanisms that control function and death of effector CD4+ T cells. Immunol Res 2006;36: 275-282.
42. Lu B, Zagouras P, Fischer JE, et al. Kinetic analysis of genomewide gene expression reveals molecule circuitries that control T cell activation and Th1/2 differentiation. Proc Natl Acad Sci USA 2004; 101: 3023-3028.
43. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25: 267-296.
44. Leary SC, Winge DR. The Janus face of copper: its expanding role in biology and the pathophysiology of disease. EMBO Rep 2007;8: 224-227.
45. Ganguly A, Chakraborty P, Banerjee K, Choudhuri SK. The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate in overcoming multidrug resistance in cancer. Eur J Pharm Sci 2014; 51: 96-109.
46. Spoerlein C, Mahal K, Schmidt H, Schobert R. Effects of chrysin, apigenin, genistein and their homoleptic copper(II) complexes on the growth and metastatic potential of cancer cells. J Inorg Biochem 2013;127: 107-115.
47. Sato TT, Machida S, Takahashi S, et al. Fas-mediated apoptosome formation is dependent on reactive oxygen species derived from mitochondrial permeability transition in Jurkat cells. J Immunol 2004;173: 285-296.